IMBCR – Institute for Myeloma & Bone Cancer Research
The only independent non-profit cancer research institute dedicated to more effective treatment, and ultimately a cure, for myeloma and bone cancer.
IMBCR’s innovative research provides cancer patients with greater longevity and an improved quality of life. Because of expanded drug therapy options and treatment combinations, IMBCR provides patients with an opportunity to enhance their chances of surviving cancer and conquer one of the hardest challenges of their lives. The team at IMBCR is working tirelessly to find a cure… and we are so close!
Multiple myeloma is a rare blood cancer of malignant cells found in the bone marrow. Multiple myeloma (active) is the most common type plasma cell cancer. However, the following are other forms of myeloma or myeloma-related conditions:
Dr. James R. Berenson formed IMBCR in 2003 to offer scientists the opportunity to work in an unencumbered environment to explore new directions in a state of the art, self-contained laboratory facility.
Dr. Berenson leads a team of dedicated scientists with extensive expertise in cancer research, particularly in the fields of metastatic cancer, cancer genetics, hematology, cellular interactions with the environment, and animal models of myeloma and other bone cancers.
IMBCR’s multiple myeloma related research is far-reaching and benefits all cancers where bone metastasis is a threat, particularly breast cancer, lung cancer, and prostate cancer as well as other types of bone marrow and blood cancer such as lymphoma and leukemia.
With your help in fundraising, IMBCR can accelerate the advancement of scientific research and ultimately help grant millions of people freedom from the symptoms of myeloma and bone cancer.